BioVaxys Technology Corp.

Liste d'échange:

CSE

Statut:

Suspended

Industrie:

Life Sciences

Symbole:

BIOV

Indice CSE:

Devise:

BioVaxys Technology Corp. est une société d'immunothérapie au stade clinique développant des plates-formes vaccinales contre le SRAS-CoV-2 et divers cancers.

Vous êtes ici

BioVaxys Technology Corp. (BIOV)

SEDAR Information

Information d'entreprise

Addresse

503, 905 West Pender St.

Vancouver, BC V6C 1L6

Canada

Téléphone

646-452-7000

Courriel

jpassin@biovaxys.com

Date d’inscription à la cote

Mercredi, novembre 21, 2018

Agent de transfert

Odyssey Trust Company

Capitalisation

Capitalisation:

220241658

Réservé à l'émission:

93537444

Company Officers

James Passin, CEO

Kenneth Kovan, COO & President

James Passin, CFO

Communiqués de presse

11/05/2024

BIOVAXYS TECHNOLOGY CORP. CLOSES SECOND TRANCHE OF PRIVATE PLACEMENT

03/05/2024

BioVaxys Technology Corp. Closes First Tranche of Private Placement

Bulletins

16/05/2024

2024-0512 - Suspension - BioVaxys Technology Corp. (BIOV)

Le 16 mai/May 2024

Effective immediately, BioVaxys Technology Corp. is suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules. A cease trade order has been issued by the Ontario Securities Commission.

For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca

Bulletins

16/05/2024

2024-0512 - Suspension - BioVaxys Technology Corp. (BIOV)

Le 16 mai/May 2024

For more information about Cease Trade Orders, visit the Canadian Securities Administrators Cease Trade Order database at www.securities-administrators.ca

24/11/2023

2023-1131 - Réintégration - BioVaxys Technology Corp. (BIOV)

le 24 Novembre/November2023

Effective immediately, BioVaxys Technology Corp. will be reinstated for trading.

The Company has rectified the situation that gave rise to the suspension.

____________________________

À compter d'aujourd'hui, BioVaxys Technology Corp. sera réintégré à la négociation.

La Société a rectifié la situation qui a donné lieu à la suspension.

05/10/2020

2020-1008 – Changement fondamental - Lions Bay Mining Corp./BioVaxys Technology Corp.

le 5 octobre/October 2020

BioVaxys Technology Corp., the issuer resulting from a Fundamental Change of Lions Bay Mining Corp. (LBM), has been approved for listing.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

BioVaxys Technology Corp. is a clinical-stage immunotherapeutics company developing vaccine platforms for SARS-CoV-2 and various cancers.

____________________________

27/04/2020

2020-0430 –Stock Split - Lions Bay Mining Corp. (LBM)

Le 27 avril/April 2020

Lions Bay Mining Corp. has announced a two (2) for one (1) stock split of its issued and outstanding common shares. Each shareholder of record as of the close of business on the record date will receive one (1) additional shares for each share held on such date.

The shares will begin trading on a split basis (ex-distribution) on April 28, 2020.

Upon completion of the split, there will be approximately 21,454,856 shares issued and outstanding.

20/11/2018

2018-1120 – Nouvelle Inscription - Lions Bay Mining Corp. (LBM)

Le 20 novembre/November 2018

The common shares of Lions Bay Mining Corp., have been approved for listing on the CSE.

Listing and disclosure documents will be available at www.thecse.com on the trading date.

Dépôts CSE

Fichier	Type	Date
BioVaxys Technology Corp. – CSE Form 6 – Certificate of Compliance	Certificat de conformité	15/05/2024
BioVaxys Technology Corp. – CSE Form 9 – Notice of Issuance or Proposed Issuance of Listed Securities	Émission proposée des titres cotés	15/05/2024
BioVaxys Technology Corp. - CSE Form 7 - Monthly Progress Report for April 2024	Rapport d'activité mensuel	06/05/2024
BioVaxys Technology Corp. – CSE Form 6 – Certificate of Compliance	Certificat de conformité	05/05/2024
BioVaxyx Technology Corp. – CSE Form 9 – Notice of Issuance or Proposed Issuance of Listed Securities	Émission proposée des titres cotés	05/05/2024
BioVaxys Technology Corp. - CSE Form 7 - Monthly Progress Report for March 2024	Rapport d'activité mensuel	04/04/2024
BIOV Q3 2023 CFO Certification	Autre	16/11/2023
BIOV Q3 2023 CEO Certification	Autre	16/11/2023
Interim Financial Statements 07 31 23	États financiers intermédiaires	10/11/2023

Vous êtes ici

BioVaxys Technology Corp.

Vous êtes ici

BioVaxys Technology Corp. (BIOV)

SEDAR Information

Formulaire de recherche

Information d'entreprise

Capitalisation

Company Officers

Communiqués de presse

Communiqués de presse

Bulletins

Bulletins

Dépôts CSE

Dépôts CSE

Connecte-toi avec nous: